CADILA PHARMS LTD
GenericsCADILA PHARMS LTD is a generic drug manufacturer focused on Cardiovascular, Metabolic, Neurology.
CADILA PHARMS LTD's Key Drugs
CADILA PHARMS LTD's core commercial portfolio centers on AMLODIPINE BESYLATE AND VALSARTAN, spanning Cardiovascular and Metabolic — its most strategically important drugs approved in the last 15 years.
CADILA PHARMS LTD's Recent FDA Approvals
New NDA/BLA approvals for CADILA PHARMS LTD over the last two years — novel drugs only, excluding generics and label supplements.
CADILA PHARMS LTD's Therapeutic Areas
CADILA PHARMS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Metabolic, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CADILA PHARMS LTD's Top Competitors
CADILA PHARMS LTD's closest competitors by therapeutic-area and drug-target overlap include Eli Lilly, Pfizer, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CADILA PHARMS LTD Pipeline Snapshot
Active clinical trials for CADILA PHARMS LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AMLODIPINE BESYLATE AND VALSARTAN leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2013-11-15
- Latest
- 2026-10-21
- Applications
- 33